Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dal K29-anti-CD3 heteroconjugate
- Development stage
- Preclinical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intraperitoneal
01
Overview
**Dal K29-anti-CD3 heteroconjugate** is an investigational, chemically linked bispecific antibody construct composed of the renal cell carcinoma-reactive monoclonal antibody Dal K29 and an anti-CD3 monoclonal antibody. It binds a cell-surface antigen associated with human renal cell carcinoma while engaging CD3 on T lymphocytes, redirecting T-cell cytotoxicity toward tumor cells. In published preclinical work, the heteroconjugate promoted potent peripheral-blood-lymphocyte-mediated lysis of human renal cell carcinoma cells in vitro, localized selectively to renal cell carcinoma xenografts, and inhibited tumor growth in an ascites xenograft model when administered with human peripheral blood lymphocytes. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/0304383594901899))
- Other names
- DAL K29-anti-CD3 heteroconjugateDal K29/anti-CD3 heteroconjugate
02
Targets
CD3 (T-cell surface glycoprotein CD3)Renal cell carcinoma-associated cell surface antigen recognized by DAL K29
Beyond the preview
Go deeper on Dal K29-anti-CD3 heteroconjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dal K29-anti-CD3 heteroconjugate.